The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Estimation of 10-year (y) cardiovascular disease (CVD) risk after cisplatin-based chemotherapy (CBCT): A multi-institutional study of 459 germ cell tumor (GCT) survivors in the Platinum study.
 
Darren R. Feldman
Consulting or Advisory Role - Bayer; Gilead Sciences (I); Seagen
Research Funding - Novartis
 
Shirin Ardeshir-Rouhani-Fard
No Relationships to Disclose
 
Patrick Monahan
No Relationships to Disclose
 
Chunkit Fung
Stock and Other Ownership Interests - GlaxoSmithKline
Consulting or Advisory Role - Bayer; Dendreon; Janssen Scientific Affairs
Research Funding - Astellas Pharma (Inst)
 
Robert James Hamilton
Honoraria - Abbvie; Astellas Pharma; Bayer; Janssen
Consulting or Advisory Role - Bayer
Research Funding - Janssen
 
David J. Vaughn
Consulting or Advisory Role - Astellas Pharma
 
Clair Beard
No Relationships to Disclose
 
Kevin C. Oeffinger
No Relationships to Disclose
 
Lawrence H. Einhorn
Stock and Other Ownership Interests - Amgen; Biogen
Consulting or Advisory Role - Celgene; ZIOPHARM Oncology
 
Sophie D. Fossa
No Relationships to Disclose
 
Howard D. Sesso
No Relationships to Disclose
 
Lois B. Travis
No Relationships to Disclose